References of "Value in Health"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPatterns of Clinical Management and Resource Utilisation for Postmenopausal Hormone-Receptor-Positive HER2-Negative (HR+ HER2-) Advanced Breast Cancer (BC) in Europe
ANDRE, Fabrice; MARINSEK, Nina; RICCI, Jean-François et al

in Value in Health (2012, November), 15(7), 419

Detailed reference viewed: 20 (4 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic burden of poor adherence with osteoporosis medications in Ireland
Hiligsmann, Mickaël ULg; McGowan, Bernie; Bennett, Kathleen et al

in Value in Health (2011), 14

Detailed reference viewed: 25 (8 ULg)
Full Text
Peer Reviewed
See detailTrend of hip fracture incidence in Belgium between 2000 and 2007 and future projections
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Detilleux, Johann ULg et al

in Value in Health (2010, November), 13(7), 303

Detailed reference viewed: 36 (12 ULg)
Full Text
Peer Reviewed
See detailCost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence.
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Value in Health (2010), 13(4), 394-401

ABSTRACT Objective: To estimate the impact of medication adherence on the cost-effectiveness of mass-screening by bone densitometry followed by alendronate therapy for women diagnosed with osteoporosis ... [more ▼]

ABSTRACT Objective: To estimate the impact of medication adherence on the cost-effectiveness of mass-screening by bone densitometry followed by alendronate therapy for women diagnosed with osteoporosis. Methods: A validated Markov microsimulation model with a Belgian health-care payer perspective and a lifetime horizon was used to assess the cost per quality-adjusted life year (QALY) gained of the screening/treatment strategy compared with no intervention. Real-world adherence to alendronate therapy and full adherence over 5 years were both investigated. The real-world adherence scenario employed adherence data from published observational studies, and medication adherence was divided into persistence, compliance, and primary adherence. Uncertainty was investigated using one-way and probabilistic sensitivity analyses. Results: At 65 years of age, the costs per QALY gained because of the screening/treatment strategy versus no intervention are euro32,008 and euro16,918 in the real-world adherence and full adherence scenarios, respectively. The equivalent values are euro80,836 and euro40,462 at the age of 55 years, and they decrease to euro10,600 and euro1229 at the age of 75 years. Sensitivity analyses show that the presence of the upfront cost of case finding has a substantial role in the impact of medication adherence on cost-effectiveness. Conclusion: This study indicates that nonadherence with osteoporosis medications substantially increases the incremental cost-effectiveness ratio of osteoporosis screening strategies. All aspects of medication adherence (i.e., compliance, persistence, and primary adherence) should therefore be reported and included in pharmacoeconomic analyses, and especially in the presence of the upfront cost of case finding (such as screening cost). [less ▲]

Detailed reference viewed: 83 (22 ULg)
Full Text
Peer Reviewed
See detailThe clinical and economic burden of nonadherence with osteoporosis medications
Hiligsmann, Mickaël ULg; Rabenda, Véronique ULg; Bruyère, Olivier ULg et al

in Value in Health (2009, October), 12(7), 444

Detailed reference viewed: 38 (13 ULg)
Full Text
Peer Reviewed
See detailDevelopment and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis.
Hiligsmann, Mickaël ULg; Ethgen, Olivier ULg; Bruyère, Olivier ULg et al

in Value in Health (2009), 12(5), 687-696

ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory ... [more ▼]

ABSTRACT Objective: Markov models are increasingly used in economic evaluations of treatments for osteoporosis. Most of the existing evaluations are cohort-based Markov models missing comprehensive memory management and versatility. In this article, we describe and validate an original Markov microsimulation model to accurately assess the cost-effectiveness of prevention and treatment of osteoporosis. Methods: We developed a Markov microsimulation model with a lifetime horizon and a direct health-care cost perspective. The patient history was recorded and was used in calculations of transition probabilities, utilities, and costs. To test the internal consistency of the model, we carried out an example calculation for alendronate therapy. Then, external consistency was investigated by comparing absolute lifetime risk of fracture estimates with epidemiologic data. Results: For women at age 70 years, with a twofold increase in the fracture risk of the average population, the costs per quality-adjusted life-year gained for alendronate therapy versus no treatment were estimated at Euro 9105 and Euro 15,325, respectively, under full and realistic adherence assumptions. All the sensitivity analyses in terms of model parameters and modeling assumptions were coherent with expected conclusions and absolute lifetime risk of fracture estimates were within the range of previous estimates, which confirmed both internal and external consistency of the model. Conclusion: Microsimulation models present some major advantages over cohort-based models, increasing the reliability of the results and being largely compatible with the existing state of the art, evidence-based literature. The developed model appears to be a valid model for use in economic evaluations in osteoporosis. [less ▲]

Detailed reference viewed: 223 (32 ULg)
Full Text
Peer Reviewed
See detailCost-effectiveness of osteoporosis screening campaign for Belgian women
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Value in Health (2007, October), 10(6), 395

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailRimonabant improves health-related quality of life in overweight/obese patients with type 2 diabetes: RIO-diabetese study
Kolotkin, R. L.; Crosby, R. D.; Scheen, André ULg

in Value in Health (2006), 9(6, NOV-DEC), 327

Detailed reference viewed: 21 (7 ULg)
Full Text
Peer Reviewed
See detailEffect of rimonabant on quality of life in overweight/obese patients
Kolotkin, R. L.; Crosby, R. D.; Scheen, André ULg et al

in Value in Health (2006), 9(3, MAY-JUN), 92

Detailed reference viewed: 15 (4 ULg)
Full Text
Peer Reviewed
See detailThe simple calculated osteoporosis risk estimation (SCORE) does not allow identification of Belgian women with a high risk of osteoporosis
Ben Sedrine, Wafa ULg; Devogelaer, Jean-Pierre; Kaufman, Jean-Marc et al

in Value in Health (2000, March), 3

Detailed reference viewed: 30 (9 ULg)
Full Text
Peer Reviewed
See detailInterest of the simple calculated osteoporosis risk estimation (SCORE) tool for a more rational use of bone densitometry
Ben Sedrine, Wafa ULg; Devogelaer, JP; Kaufman, JM et al

in Value in Health (2000, March), 3

Detailed reference viewed: 18 (5 ULg)